Sponsor:
Washington University School of Medicine
Code:
NCT07723651
Conditions
Metastatic Prostate Cancer
Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one
FTT-PET/CT
EnhanceAR-Seq
Brief summary:
Conditions
Metastatic Prostate Cancer
Prostate Cancer
Study ID
NCT07723651
Start date
Nov 30, 2026
Status verified date
Nov, 2026
Completion date
May 31, 2032
Anticipated
Primary completion date
May 31, 2032
Anticipated
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
75 participants
Anticipated
Intervention Model
Single group
Primary purpose
Diagnostic
Arms
experimental: FTT-PET/CT
Interventions
1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one
FTT-PET/CT
EnhanceAR-Seq
Primary outcome measure
Central contacts
Locations
Washington University School of Medicine
Recruiting
St Louis, Missouri, United States, 63110
Contacts
Sponsor
Washington University School of Medicine
Last update posted
Nov 20, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.